OTCMKTS:BICX Biocorrx Q2 2026 Earnings Report $0.23 -0.01 (-5.13%) As of 08/19/2026 09:30 AM Eastern ProfileEarnings HistoryForecast Biocorrx EPS ResultsActual EPS-$0.03Consensus EPS -$0.05Beat/MissBeat by +$0.02One Year Ago EPSN/ABiocorrx Revenue ResultsActual Revenue$0.09 millionExpected Revenue$0.24 millionBeat/MissMissed by -$152.00 thousandYoY Revenue GrowthN/ABiocorrx Announcement DetailsQuarterQ2 2026Date8/14/2026TimeDuring Market HoursConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Biocorrx Earnings HeadlinesBiocorrx Inc. (OTCMKTS:BICX) Short Interest UpdateAugust 14, 2026 | americanbankingnews.comBioCorRx Inc.April 21, 2026 | marketwatch.comLook at this $5 stock’s addressA small public company trading under $5 a share operates inside the secure perimeter of Kennedy Space Center, right alongside SpaceX and Blue Origin. It holds a special agreement to use a multi-billion dollar federal launch facility for just $500, and its customer list already includes the Pentagon, Lockheed Martin, and GE Aerospace. Most Wall Street analysts have not caught on yet, but a major milestone could change that soon.August 20 at 1:00 AM | Freedom Financial (Ad)BioCorRx, Inc. Announces Issuance of U.S. Patent Supporting Its Biodegradable Naltrexone Implant TechnologyMarch 11, 2026 | finance.yahoo.comBioCorRx, Inc. Announces Initiation of Clinical Study by Majority-Owned Subsidiary BioCorRx Pharmaceuticals, Inc. Evaluating Long-Acting Naltrexone Implant With or Without ...January 15, 2026 | finance.yahoo.comBioCorRx Announces Appointment of Louis Lucido as Board ChairJanuary 6, 2026 | finance.yahoo.comSee More Biocorrx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Biocorrx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biocorrx and other key companies, straight to your email. Email Address About BiocorrxBiocorrx (OTCMKTS:BICX), through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.View Biocorrx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Walmart's Post-Earnings Drop Could Be a Buying Opportunity3 Energy Stocks Raising Dividends as the Sector Surges5 Reasons the S&P 500 Could Keep Rallying Through Year-EndSociedad Química y Minera’s Lithium Boom Is Back, But Iodine Steals the ShowNasdaq’s 23-Hour Trading Push Could Turn Global Liquidity Into a Growth EngineForget Chips: These 3 Stocks Are Building the AI Data Center BoomAnalog Devices’ AI Pivot Could Push Shares to Fresh Highs Upcoming Earnings PDD (8/24/2026)Bank Of Montreal (8/25/2026)Bank of Nova Scotia (8/25/2026)Intuit (8/25/2026)Salesforce (8/26/2026)CrowdStrike (8/26/2026)NVIDIA (8/26/2026)Synopsys (8/26/2026)Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
